Home › Trials › NCT07843472
Clinical trial Recruiting at 3 sites Phase 3 Interventional Ages 40 and up

Petrelintide for weight loss in people with overweight/obesity and heart disease

Official title: A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease

Run by Hoffmann-La Roche · NCT07843472 · Data updated 2026-11-12

This study tests whether petrelintide helps people with overweight or obesity and cardiovascular disease lose weight when added to a reduced-calorie diet and more physical activity, compared with a placebo.

Quick facts

PhasePhase 3
Study typeInterventional
Ages40 Years and up
SexAll
Enrollment2500 (estimated)
SponsorHoffmann-La Roche
Industry-sponsored
Locations3 sites (Anniston, Alabama and 2 other locations)
StatusRecruiting
StartedSeptember 30, 2026
Main results expectedJuly 28, 2030
Study endsOctober 6, 2030
Registry record updatedOctober 7, 2026
Trial IDNCT07843472 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with BMI ≥ 27 kg/m² and established cardiovascular disease who have tried but not succeeded with dieting before.

Probably not a fit

Individuals without overweight/obesity or with non-established cardiovascular disease, or those who cannot participate in the diet/exercise program, may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 interventional trial compares petrelintide to placebo in adults with BMI 27 or higher and established cardiovascular disease. All participants receive a structured lifestyle program that includes a reduced-calorie diet and increased physical activity. The study aims to determine the drug’s effect on weight change and safety over time. Excluded are individuals with type 1 diabetes or prior petrelintide or amylin analog use, and those who have not previously failed diet attempts. The trial is sponsored by Hoffmann-La Roche with Zealand Pharma and is conducted at multiple sites in the United States.

Why it matters

Potential benefit: If successful, participants could lose more weight and improve health markers related to obesity and cardiovascular disease.

How similar studies have gone: Prior studies of amylin analogs in weight management have shown potential benefits, though results vary by population and context.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Participants with BMI ≥ 27 kg/m² and established CVD
* History of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion Criteria:

* Known history of Type 1 diabetes mellitus
* Current or previous treatment with petrelintide or any other amylin analog

Where it's running

  • Pinnacle Research Group
    Anniston, Alabama, United States     Recruiting
  • Institute for Metabolic Research Los Angeles
    Los Angeles, California, United States     Recruiting
  • Progressive Medical Research
    Port Orange, Florida, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Obesity or Overweight 11Cardiovascular Disease 397Hoffmann-La Roche 78
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.